查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1985586

标靶定序市场：依产品类型、平台、最终用户和应用划分－2026-2032年全球市场预测

Targeted Sequencing Market by Product Type, Platform, End User, Application - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 196 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2025 年，标靶定序市场价值将达到 91.8 亿美元，到 2026 年将成长至 111 亿美元，到 2032 年将达到 349.7 亿美元，年复合成长率为 21.04%。

主要市场统计数据
基准年 2025 91.8亿美元
预计年份：2026年 111亿美元
预测年份 2032 349.7亿美元
复合年增长率 (%) 21.04%

对目标序列进行简明策略展望，重点在于技术整合、临床效用以及对决策者的营运影响。

在化学、仪器和数据分析技术的进步推动下，标靶定序已从一项小众实验室技术发展成为精准研究和临床工作流程的基础。本执行摘要整合了技术发展、应用趋势、监管趋势和竞争格局的关键进展，旨在帮助研究机构、诊断检查室和生命科学公司的管理人员制定策略重点和投资决策。

化学技术的进步、扩充性的仪器架构以及日益成熟的生物资讯学如何重新定义整个标靶定序工作流程中的临床和研究效用。

近年来，标靶定序解决方案的开发、部署和商业化方式发生了翻天覆地的变化。首先，化学和样品製备的创新缩短了周转时间，提高了标靶效率，使诊断检查室能够提供更快、更可靠的结果。伴随这些技术进步，一种可扩展的仪器架构已经建立，涵盖了从分散式实验室的桌上型系统到分散式检查定序中心的高通量平台，从而拓展了其应用范围，从单例患者诊断扩展到大规模队列研究。

2025 年关税调整如何促进供应链韧性、在地化投资以及整个目标序列生态系统策略采购政策的转变。

美国2025年实施的关税调整的累积影响，已在目标序列的整个价值链中造成了明显的摩擦，影响了筹资策略、定价趋势和供应连续性。关税相关的成本压力对资本设备和耗材均造成了衝击，推高了进口到美国的设备和试剂的到货成本。因此，供应商和最终用户正在修订其采购计划，并加快供应商多元化，以维持营运预算和专案进度。

将产品架构、平台选择、最终用户优先顺序和应用需求与策略决策流程连结起来的基于详细细分的洞察。

细分市场分析揭示了清晰的技术架构、用户需求和商业性压力，这些资讯应指南产品组合和市场进入策略。根据产品类型，市场可分为三大类：仪器、试剂和试剂盒以及软体和服务。仪器包括适用于分散式低通量检测的桌上型定序仪，以及专为中心检查室和大规模研究设计的高通量定序仪。试剂和试剂盒包括基于扩增子、基于杂合反应和分子反转探针的各种形式，每种形式都针对不同的标靶范围、样本类型和灵敏度要求进行了最佳化。软体和服务涵盖生物资讯服务和数据分析软体，反映了对结果解读、流程检验和法规遵循报告日益增长的需求。

影响美洲、欧洲、中东和非洲以及亚太地区招募和商业化的相对区域趋势和策略挑战。

区域趋势差异显着，影响美洲、欧洲、中东和非洲以及亚太地区的技术采纳、监管策略和伙伴关係模式。在美洲，对诊断基础设施和大规模临床研究基地的投资正在推动高通量平台和整合生物资讯解决方案的快速普及，这些方案支援转化研究和集中式检测网路。该地区的相关人员优先考虑与当地监管机构的监管协调、临床检验和证据生成，以支持临床应用和支付方参与。

仪器、试剂和生物资讯学的专业知识，结合伙伴关係和服务模式，如何决定永续的竞争地位。

企业层面的趋势反映了竞争格局中专业化、整合和服务差异化正在决定企业定位。专注于仪器创新的供应商强调通量、自动化和「从样本到结果」的工作流程，以减少人工操作并实现分散式检查。同时，试剂和试剂盒供应商则专注于检测的稳健性、批间一致性以及与多个平台的易于集成，以最大限度地满足其目标应用场景。

领导者可采取的策略重点，以增强互通性、监管合应对力、供应链韧性和实证商业化。

产业领导者应协调一系列策略行动，以增强韧性、加速产品普及并抓住更高附加价值的机会。首先，应优先考虑跨平台的互通性和开放标准，使客户能够以最小的阻力整合仪器、试剂和分析功能。这将降低买家的抵触情绪，并扩大目标用户群。其次，应在产品生命週期的早期阶段投资于法规遵循和临床证据能力，以缩短产品投入临床实用化的时间，并为保险报销谈判提供支援。

混合研究框架结合了相关人员访谈、技术文献整合和监管审查，以确保获得与背景相关的、可操作的见解。

本研究利用结构化访谈、技术检验审查和跨区域政策分析，整合一手和二手信息，对靶向测序趋势进行全面评估。研究人员对检查室管理人员、检测开发人员、采购经理和监管专家进行了初步的定性访谈，以了解营运挑战、应用驱动因素和证据产生策略。这些对话有助于解读不同平台架构之间的技术权衡，并为商业化和产品开发提供指导指南。

将策略挑战和操作指南相结合，以将标靶定序的进展转化为可持续的临床和商业性影响。

总之，标靶定序技术处于技术能力和临床需求的策略性交会点，能够提供精准的基因组分析，从而支持诊断、治疗和公共卫生领域的应用。化学、仪器和生物资讯学的进步正在拓展这项技术的效用，并推动将检测方法与整合分析能力相结合的新型经营模式的出现。同时，监管预期、支付方审查和贸易政策等外部因素正在影响产品从研发到常规应用的转变。

目录

第一章：序言

第二章：调查方法

  • 调查设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查的前提
  • 研究限制

第三章执行摘要

  • 首席主管观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 市场进入策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会映射
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章 标靶定序市场：依产品类型划分

  • 装置
    • 桌上型音序器
    • 高通量定序仪
  • 试剂和试剂盒
    • 基于扩增子的试剂盒
    • 杂合反应基础试剂盒
    • 基于MIP的试剂盒
  • 软体服务
    • 生物资讯服务
    • 数据分析软体

第九章 标靶定序市场：依平台划分

  • 扩增子序列
    • 多重PCR
    • 基于UMI的定序
  • 混合捕获
    • 基于诱饵的捕获
    • 基于探针的捕获
  • 分子反转探针
    • 用于 CNV 分析的 MIP 探针
    • 用于SNP检测的MIP探针

第十章 标靶定序市场：依最终用户划分

  • 学术和研究机构
  • 医院和诊断中心
    • 即时检验检查室
    • 参考实验室
  • 製药和生物技术公司
    • 临床研究机构
    • 药物发现部门

第十一章 标靶定序市场：按应用领域划分

  • 生物标记发现
    • 药物基因体学学生物标誌物
    • 预测性生物标记
  • 遗传性疾病
    • 产前检查
    • 罕见疾病的诊断
  • 感染疾病
    • 抗生素抗药性检测
    • 病原体检测
  • 肿瘤学
    • 诊断
    • 预后诊断
    • 治疗诊断学

第十二章 标靶定序市场：按地区划分

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十三章 标靶定序市场：依组别划分

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十四章 标靶定序市场：依国家划分

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十五章：美国标靶定序市场

第十六章：中国标靶定序市场

第十七章 竞争格局

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • 10x Genomics, Inc.
  • A-Alpha Bio, Inc.
  • Agilent Technologies, Inc.
  • Azenta Life Sciences
  • BGI Genomics Co., Ltd.
  • Bio-Rad Laboratories, Inc.
  • CD Genomics
  • DH Life Sciences, LLC
  • Element Biosciences
  • F. Hoffmann-La Roche Ltd.
  • Illumina, Inc.
  • LGC Limited
  • Macrogen, Inc.
  • MGI Tech Co., Ltd.
  • Oxford Nanopore Technologies PLC
  • Pacific Biosciences of California, Inc.
  • Paragon Genomics, Inc.
  • PerkinElmer, Inc.
  • Psomagen, Inc.
  • QIAGEN NV
  • Singular Genomics Systems, Inc.
  • Takara Bio Inc.
  • Tecan Trading AG
  • Thermo Fisher Scientific Inc.
  • Twist Bioscience Corporation
Product Code: MRR-1E2F1ED7E6A7

The Targeted Sequencing Market was valued at USD 9.18 billion in 2025 and is projected to grow to USD 11.10 billion in 2026, with a CAGR of 21.04%, reaching USD 34.97 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 9.18 billion
Estimated Year [2026] USD 11.10 billion
Forecast Year [2032] USD 34.97 billion
CAGR (%) 21.04%

A concise strategic orientation to targeted sequencing highlighting technological integration, clinical utility, and operational implications for decision-makers

Targeted sequencing has evolved from a niche laboratory technique into a cornerstone of precision research and clinical workflows, driven by advances in chemistry, instrumentation, and data analytics. This executive summary synthesizes critical developments across technology, adoption patterns, regulatory dynamics, and competitive activity to support senior leaders in research organizations, diagnostics laboratories, and life sciences companies as they weigh strategic priorities and investment decisions.

The narrative that follows positions targeted sequencing within a broader genomics ecosystem where sample throughput, assay specificity, and bioinformatics sophistication now determine commercial and clinical differentiation. Key drivers include the demand for focused genomic interrogation in oncology, inherited disease diagnostics, and infectious disease surveillance, as well as the need for cost-efficient, high-confidence variant detection in routine workflows. At the same time, evolving regulatory expectations and reimbursement frameworks are shaping how assays translate from the bench to bedside.

This introduction frames targeted sequencing as a dynamic, modular platform space where instruments, consumables, and software integrate into end-to-end solutions. It underscores the importance of interoperability and workflow optimization while highlighting the strategic choices that organizations face when selecting platforms, designing panels, and building analytic pipelines. The rest of the summary elaborates on technological inflection points, external policy impacts, segmentation nuances, regional performance differentials, and actionable recommendations for leaders seeking to capture value from this rapidly maturing domain.

How chemistry advances, scalable instrument architectures, and maturing bioinformatics are jointly redefining clinical and research utility across targeted sequencing workflows

The past several years have produced transformative shifts that reshape how stakeholders develop, deploy, and monetize targeted sequencing solutions. First, chemistry and library-preparation innovations have compressed turnaround times and improved on-target efficiency, enabling diagnostics laboratories to deliver faster, higher-confidence results. These technical gains have been paralleled by instrument architectures that scale from benchtop systems for decentralized testing to high-throughput platforms for centralized sequencing hubs, thereby expanding the addressable use-cases from single-patient diagnostics to large-scale cohort studies.

Concurrently, bioinformatics has moved from a supporting role to a strategic capability. Sophisticated variant callers, standardized pipelines, and explainable annotation layers now drive clinical-grade interpretations and reduce time-to-decision for clinicians and researchers. This maturation of software and services increases the value capture for vendors offering integrated analytics and paves the way for subscription or outcome-linked commercial models.

Market dynamics also reflect a shift toward modular ecosystems where reagents, kits, and third-party analytical tools coexist. Organizations increasingly prefer flexible platform strategies that decouple instrument procurement from reagent sourcing to avoid vendor lock-in and maintain agility in assay design. At the same time, partnerships between sequencing providers, reagent developers, and bioinformatics firms have intensified, facilitating bundled solutions that accelerate adoption in hospital laboratories and research centers.

Regulatory and reimbursement landscapes are further influencing product design and commercial rollout. Regulatory frameworks that emphasize clinical validation and traceability have prompted providers to strengthen quality systems, produce robust validation datasets, and engage earlier with regulators. Meanwhile, payers are beginning to demand stronger evidence of clinical utility and cost-effectiveness for broad deployment, encouraging developers to align evidence-generation strategies with reimbursement needs. Taken together, these shifts are redefining the competitive logic of the field and guiding where capital and talent will concentrate in the near term.

How 2025 tariff adjustments catalyzed supply-chain resilience, localization investments, and strategic sourcing shifts across the targeted sequencing ecosystem

The cumulative impact of the United States tariff adjustments implemented in 2025 has introduced measurable friction across the targeted sequencing value chain, influencing sourcing strategies, pricing dynamics, and supply continuity. Tariff-related cost pressures have affected both capital equipment and consumables, elevating landed costs for instruments and reagents imported into the United States. As a result, providers and end users have recalibrated procurement plans and accelerated vendor diversification to maintain operational budgets and program timelines.

In response to these trade measures, many suppliers intensified efforts to localize production, either by shifting key manufacturing steps to domestic facilities or by qualifying alternative suppliers in tariff-exempt jurisdictions. These adjustments reduced immediate exposure to import levies but required short-term capital investments and supply-chain revalidation. For some reagent and kit manufacturers, the need to requalify manufacturing sites and to replicate quality-control processes introduced incremental lead times and batch equivalency assessments that impacted product availability.

Beyond manufacturing shifts, the tariff environment amplified the strategic importance of supply-chain resilience. Organizations placed greater emphasis on inventory buffering, multi-sourcing contracts, and contractual protection clauses to mitigate the risk of sudden cost escalation. Moreover, procurement teams increasingly incorporated total landed cost analyses that accounted for duties, compliance overhead, and potential delays. These practices favored suppliers with geographically distributed manufacturing footprints and robust logistics capabilities.

Finally, the tariff adjustments have influenced collaborative and commercial behaviors. Strategic partnerships and co-investment models gained traction as vendors and service providers sought to share localization costs and to secure preferential access to critical components. Concurrently, some academic and research institutions explored reagent sharing consortia and centralized procurement frameworks to preserve research continuity. While tariffs introduced near-term cost and operational complexity, they also catalyzed supply-chain modernization and encouraged stakeholders to strengthen long-term resilience strategies.

Deep segmentation-driven insights linking product architectures, platform choices, end-user priorities, and application requirements to strategic decision pathways

Segmentation analysis reveals distinct technology stacks, user needs, and commercial pressures that should guide portfolio and go-to-market strategies. Based on product type, the landscape separates into Instruments, Reagents & Kits, and Software & Services. Instruments span benchtop sequencers suited for decentralized, lower-throughput testing and high-throughput sequencers designed for central laboratories and large-scale studies. Reagents and kits include amplicon-based, hybridization-based, and molecular inversion probe formats, each optimized for different target breadths, sample types, and sensitivity requirements. Software and services cover bioinformatics services and data analysis software, reflecting the growing demand for interpretation, pipeline validation, and regulatory-grade reporting.

Platform segmentation further clarifies technical trade-offs and application fit. Amplicon sequencing workflows, including multiplex PCR and unique molecular identifier (UMI)-based approaches, deliver high sensitivity for focused panels and low-input samples. Hybrid capture strategies, realized through baits-based and probe-based capture formats, enable broader panel coverage and improved uniformity for complex targets. Molecular inversion probes are tailored for highly multiplexed detection and include probes optimized for copy-number variation analysis and single-nucleotide polymorphism detection, offering cost-efficient scalability for targeted discovery and genotyping projects.

End-user segmentation highlights differing operational imperatives and procurement patterns. Academic and research institutes, including both private research labs and public research labs, prioritize methodological flexibility, publication-grade data quality, and grant-driven timelines. Hospitals and diagnostic centers, encompassing point-of-care laboratories and reference laboratories, emphasize regulatory compliance, reproducibility, and rapid clinical turnaround. Pharmaceutical and biotechnology companies, including clinical research organizations and drug discovery units, focus on assay robustness, scalability for clinical trials, and integration with biomarker and companion diagnostic programs.

Application segmentation underscores the range of use-cases that drive platform choice and partner selection. Biomarker discovery applications, spanning pharmacogenomic and predictive biomarkers, require deep coverage and high annotation fidelity. Genetic disease workflows, including prenatal testing and rare disease diagnosis, demand validated assays with low false-negative rates and clear clinical reporting. Infectious disease applications-antibiotic resistance testing and pathogen detection-prioritize rapid, sensitive assays that accommodate diverse sample matrices. Oncology applications across diagnostics, prognostics, and theranostics require flexible panel design, compatibility with liquid biopsies, and analytical pipelines that support clinical decision-making. Understanding these segmentation interdependencies enables stakeholders to align product development, commercialization, and service offerings with clearly defined technical and clinical requirements.

Comparative regional dynamics and strategic imperatives across the Americas, Europe Middle East & Africa, and Asia-Pacific shaping adoption and commercialization

Regional dynamics vary substantially, shaping technology adoption, regulatory strategies, and partnership models across the Americas, Europe, Middle East & Africa, and Asia-Pacific. In the Americas, investment in diagnostic infrastructure, coupled with a large clinical research base, encourages rapid uptake of high-throughput platforms and integrated bioinformatics solutions that support translational research and centralized testing networks. Stakeholders in this region prioritize regulatory alignment with local authorities, clinical validation, and evidence generation to support clinical adoption and payer engagement.

Within Europe, Middle East & Africa, diverse regulatory regimes and varying healthcare funding models create differentiated adoption pathways. Western European markets tend to emphasize interoperability, standardized data reporting, and quality systems, while emerging markets in the region focus on access, capacity building, and cost-effective workflows. Collaborative public-private initiatives and regional reference laboratory networks play an outsized role in scaling targeted sequencing for public health and oncology programs.

Asia-Pacific demonstrates rapid capacity expansion driven by public investment, large patient populations, and ambitious precision-medicine initiatives. Several countries are investing heavily in localized manufacturing, domestic R&D, and national genomics programs, which accelerates demand for both benchtop systems for decentralized testing and high-throughput platforms for population-scale studies. Across the region, partnerships between global vendors and local service providers or manufacturers help tailor offerings to regulatory expectations and price sensitivity while advancing technology transfer and workforce development.

Across all regions, cross-border collaboration, data harmonization efforts, and regulatory convergence are emerging themes that support multinational clinical studies and diagnostic rollouts. Regional infrastructure maturity, payer policies, and local manufacturing capabilities continue to shape supplier selection and commercial strategies, underscoring the need for geographically nuanced go-to-market plans.

How specialization in instruments, reagents, and bioinformatics combined with partnerships and service models determines sustainable competitive positioning

Company-level trends reflect a competitive landscape where specialization, integration, and service differentiation determine positioning. Vendors focused on instrument innovation emphasize throughput, automation, and sample-to-answer workflows that reduce hands-on time and enable decentralized testing. Conversely, reagent and kit providers concentrate on assay robustness, lot-to-lot consistency, and ease of integration with multiple platforms to maximize addressable use cases.

Software and service providers are increasingly differentiating on clinical interpretive capabilities, regulatory readiness, and the ability to deliver validated pipelines that meet laboratory accreditation requirements. Managed services, cloud-enabled analytics, and certified reference databases have become important value levers for organizations seeking to outsource complex analytics or to accelerate clinical deployment. Strategic alliances between instrument manufacturers and bioinformatics firms have proliferated to offer bundled solutions that shorten validation timelines and improve customer retention.

Emerging companies and specialized service providers play a crucial role in niche innovation, developing novel chemistries, bespoke capture probes, and highly optimized panels for hard-to-sequence targets. These smaller entities often collaborate with larger partners for scale-up and distribution while retaining agility in product development and customer engagement. Meanwhile, contract research organizations and clinical CROs expand their offerings to include targeted sequencing assay development and sample management services, responding to sponsors' demand for end-to-end trial-ready workflows.

Overall, successful companies combine technical excellence with robust quality systems, clear regulatory strategies, and customer-centric commercialization models. Firms that invest in evidence generation, interoperability, and flexible commercial structures are better positioned to capture long-term value as clinical and research adoption continues to mature.

Practical strategic priorities for leaders to enhance interoperability, regulatory readiness, supply-chain resilience, and evidence-driven commercialization

Industry leaders should pursue a coordinated set of strategic actions to strengthen resilience, accelerate adoption, and capture higher-value opportunities. First, prioritize platform interoperability and open standards so that customers can integrate instruments, reagents, and analytics with minimal friction; this reduces buyer resistance and expands the addressable user base. Second, invest in regulatory and clinical-evidence capabilities early in the product lifecycle to shorten time-to-clinical utility and to support reimbursement discussions.

Third, diversify manufacturing and sourcing footprints to mitigate tariff and geopolitical risk while ensuring consistent supply for critical consumables. Coupled with this, develop flexible commercial models-such as reagent-as-a-service, subscription analytics, or outcome-linked agreements-that align vendor incentives with customers' operational and fiscal objectives. Fourth, strengthen partnerships with clinical laboratories, academic consortia, and pharmaceutical sponsors to co-develop panels and generate real-world evidence that demonstrates utility across diagnostic and therapeutic workflows.

Fifth, prioritize talent development in bioinformatics and assay validation to maintain high analytical standards and to accelerate time-to-insight for customers. Sixth, implement rigorous quality-management systems and documentation practices to streamline regulatory submissions and to facilitate multi-jurisdictional approvals. Finally, adopt a data governance posture that emphasizes interoperability, patient privacy, and secure cloud architectures to enable scalable analytics while preserving compliance.

Collectively, these actions create a durable competitive foundation by aligning product roadmaps with customer needs, regulatory realities, and operational constraints, enabling organizations to convert technical capabilities into sustainable commercial outcomes.

A mixed-methods research framework combining stakeholder interviews, technical literature synthesis, and regulatory review to ensure context-aware actionable insights

This research synthesizes primary and secondary inputs to generate a comprehensive assessment of targeted sequencing dynamics, drawing on structured interviews, technical validation reviews, and cross-regional policy analysis. Primary qualitative interviews were conducted with laboratory directors, assay developers, procurement leaders, and regulatory specialists to capture operational pain points, adoption drivers, and evidence-generation strategies. These conversations informed the interpretation of technical trade-offs across platform architectures and guided recommendations for commercialization and product development.

Secondary inputs included peer-reviewed literature, regulatory guidance documents, clinical-pathway analyses, and published technical performance studies that describe assay sensitivity, specificity, and workflow constraints. The analysis also leveraged publicly available clinical trial registries, patent filings, and conference proceedings to map innovation trajectories and to identify emerging chemistries and analytic approaches. Comparative policy reviews assessed regional regulatory expectations, quality standards, and reimbursement frameworks that influence clinical deployment.

Analytical approaches combined qualitative synthesis with cross-sectional benchmarking of technology attributes, user needs, and regional enablers. Validation steps included triangulating interview insights with technical performance claims and regulatory precedents, ensuring the conclusions reflect real-world implementation considerations. Limitations of the research are acknowledged where proprietary performance data or confidential commercial agreements restrict visibility; where appropriate, recommendations emphasize adaptable strategies that perform under varying evidentiary and regulatory conditions.

This mixed-methods approach produces actionable, context-aware insights intended to support decision-making across R&D planning, commercial strategy, and operational risk management.

Synthesis of strategic imperatives and operational guidance to translate targeted sequencing advancements into durable clinical and commercial impact

In conclusion, targeted sequencing occupies a strategic intersection between technological capability and clinical need, offering focused genomic interrogation that supports diagnostics, therapeutics, and public health applications. Advances in chemistry, instrumentation, and bioinformatics have expanded the technique's utility while driving new commercial models that couple assays with integrated analytics. At the same time, external forces-including regulatory expectations, payer scrutiny, and trade policy-shape how products move from development into routine use.

Stakeholders that align product development with rigorous evidence-generation, adopt supply-chain diversification, and prioritize interoperability will be best positioned to capture sustained value. Regional nuances require tailored strategies: centralized high-throughput approaches work well where regulatory and reimbursement systems support scale, while benchtop and decentralized solutions address demand for rapid, point-of-care decision-making. Finally, companies that combine technical excellence with thoughtful commercial and regulatory execution will find the greatest opportunities to differentiate and to secure long-term partnerships with diagnostic laboratories, healthcare systems, and pharmaceutical sponsors.

This executive summary provides a strategic foundation for leaders seeking to prioritize investments, design collaborative programs, and navigate operational risks in the evolving targeted sequencing landscape. The recommendations and insights herein are intended to support disciplined decision-making and to accelerate the translation of targeted sequencing innovation into measurable clinical and research impact.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Targeted Sequencing Market, by Product Type

  • 8.1. Instruments
    • 8.1.1. Benchtop Sequencers
    • 8.1.2. High-Throughput Sequencers
  • 8.2. Reagents & Kits
    • 8.2.1. Amplicon-Based Kits
    • 8.2.2. Hybridization-Based Kits
    • 8.2.3. MIP-Based Kits
  • 8.3. Software & Services
    • 8.3.1. Bioinformatics Services
    • 8.3.2. Data Analysis Software

9. Targeted Sequencing Market, by Platform

  • 9.1. Amplicon Sequencing
    • 9.1.1. Multiplex PCR
    • 9.1.2. UMI-Based Sequencing
  • 9.2. Hybrid Capture
    • 9.2.1. Baits-Based Capture
    • 9.2.2. Probe-Based Capture
  • 9.3. Molecular Inversion Probes
    • 9.3.1. MIP Probes For CNV Analysis
    • 9.3.2. MIP Probes For SNP Detection

10. Targeted Sequencing Market, by End User

  • 10.1. Academic & Research Institutes
  • 10.2. Hospitals & Diagnostic Centers
    • 10.2.1. Point-of-Care Laboratories
    • 10.2.2. Reference Laboratories
  • 10.3. Pharmaceutical & Biotechnology Companies
    • 10.3.1. Clinical Research Organizations
    • 10.3.2. Drug Discovery Units

11. Targeted Sequencing Market, by Application

  • 11.1. Biomarker Discovery
    • 11.1.1. Pharmacogenomic Biomarkers
    • 11.1.2. Predictive Biomarkers
  • 11.2. Genetic Diseases
    • 11.2.1. Prenatal Testing
    • 11.2.2. Rare Disease Diagnosis
  • 11.3. Infectious Diseases
    • 11.3.1. Antibiotic Resistance Testing
    • 11.3.2. Pathogen Detection
  • 11.4. Oncology
    • 11.4.1. Diagnostics
    • 11.4.2. Prognostics
    • 11.4.3. Theranostics

12. Targeted Sequencing Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Targeted Sequencing Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Targeted Sequencing Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. United States Targeted Sequencing Market

16. China Targeted Sequencing Market

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025
  • 17.5. 10x Genomics, Inc.
  • 17.6. A-Alpha Bio, Inc.
  • 17.7. Agilent Technologies, Inc.
  • 17.8. Azenta Life Sciences
  • 17.9. BGI Genomics Co., Ltd.
  • 17.10. Bio-Rad Laboratories, Inc.
  • 17.11. CD Genomics
  • 17.12. DH Life Sciences, LLC
  • 17.13. Element Biosciences
  • 17.14. F. Hoffmann-La Roche Ltd.
  • 17.15. Illumina, Inc.
  • 17.16. LGC Limited
  • 17.17. Macrogen, Inc.
  • 17.18. MGI Tech Co., Ltd.
  • 17.19. Oxford Nanopore Technologies PLC
  • 17.20. Pacific Biosciences of California, Inc.
  • 17.21. Paragon Genomics, Inc.
  • 17.22. PerkinElmer, Inc.
  • 17.23. Psomagen, Inc.
  • 17.24. QIAGEN N.V.
  • 17.25. Singular Genomics Systems, Inc.
  • 17.26. Takara Bio Inc.
  • 17.27. Tecan Trading AG
  • 17.28. Thermo Fisher Scientific Inc.
  • 17.29. Twist Bioscience Corporation

LIST OF FIGURES

  • FIGURE 1. GLOBAL TARGETED SEQUENCING MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL TARGETED SEQUENCING MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL TARGETED SEQUENCING MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY PLATFORM, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. UNITED STATES TARGETED SEQUENCING MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 12. CHINA TARGETED SEQUENCING MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL TARGETED SEQUENCING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY INSTRUMENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY INSTRUMENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY INSTRUMENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY BENCHTOP SEQUENCERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY BENCHTOP SEQUENCERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY BENCHTOP SEQUENCERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY HIGH-THROUGHPUT SEQUENCERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY HIGH-THROUGHPUT SEQUENCERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY HIGH-THROUGHPUT SEQUENCERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY REAGENTS & KITS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY REAGENTS & KITS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY REAGENTS & KITS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY REAGENTS & KITS, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY AMPLICON-BASED KITS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY AMPLICON-BASED KITS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY AMPLICON-BASED KITS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY HYBRIDIZATION-BASED KITS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY HYBRIDIZATION-BASED KITS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY HYBRIDIZATION-BASED KITS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY MIP-BASED KITS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY MIP-BASED KITS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY MIP-BASED KITS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY SOFTWARE & SERVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY SOFTWARE & SERVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY SOFTWARE & SERVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY BIOINFORMATICS SERVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY BIOINFORMATICS SERVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY BIOINFORMATICS SERVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY DATA ANALYSIS SOFTWARE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY DATA ANALYSIS SOFTWARE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY DATA ANALYSIS SOFTWARE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY AMPLICON SEQUENCING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY AMPLICON SEQUENCING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY AMPLICON SEQUENCING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY AMPLICON SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY MULTIPLEX PCR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY MULTIPLEX PCR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY MULTIPLEX PCR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY UMI-BASED SEQUENCING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY UMI-BASED SEQUENCING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY UMI-BASED SEQUENCING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY HYBRID CAPTURE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY HYBRID CAPTURE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY HYBRID CAPTURE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY HYBRID CAPTURE, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY BAITS-BASED CAPTURE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY BAITS-BASED CAPTURE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY BAITS-BASED CAPTURE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY PROBE-BASED CAPTURE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY PROBE-BASED CAPTURE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY PROBE-BASED CAPTURE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY MOLECULAR INVERSION PROBES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY MOLECULAR INVERSION PROBES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY MOLECULAR INVERSION PROBES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY MOLECULAR INVERSION PROBES, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY MIP PROBES FOR CNV ANALYSIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY MIP PROBES FOR CNV ANALYSIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY MIP PROBES FOR CNV ANALYSIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY MIP PROBES FOR SNP DETECTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY MIP PROBES FOR SNP DETECTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY MIP PROBES FOR SNP DETECTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY HOSPITALS & DIAGNOSTIC CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY HOSPITALS & DIAGNOSTIC CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY HOSPITALS & DIAGNOSTIC CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY HOSPITALS & DIAGNOSTIC CENTERS, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY POINT-OF-CARE LABORATORIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY POINT-OF-CARE LABORATORIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY POINT-OF-CARE LABORATORIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY REFERENCE LABORATORIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY REFERENCE LABORATORIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY REFERENCE LABORATORIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY CLINICAL RESEARCH ORGANIZATIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY CLINICAL RESEARCH ORGANIZATIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY CLINICAL RESEARCH ORGANIZATIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY DRUG DISCOVERY UNITS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY DRUG DISCOVERY UNITS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY DRUG DISCOVERY UNITS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY BIOMARKER DISCOVERY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY BIOMARKER DISCOVERY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY BIOMARKER DISCOVERY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY BIOMARKER DISCOVERY, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY PHARMACOGENOMIC BIOMARKERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY PHARMACOGENOMIC BIOMARKERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY PHARMACOGENOMIC BIOMARKERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY PREDICTIVE BIOMARKERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY PREDICTIVE BIOMARKERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY PREDICTIVE BIOMARKERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY GENETIC DISEASES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY GENETIC DISEASES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY GENETIC DISEASES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY GENETIC DISEASES, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY PRENATAL TESTING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY PRENATAL TESTING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY PRENATAL TESTING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY RARE DISEASE DIAGNOSIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY RARE DISEASE DIAGNOSIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY RARE DISEASE DIAGNOSIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY INFECTIOUS DISEASES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY INFECTIOUS DISEASES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 115. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 116. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY ANTIBIOTIC RESISTANCE TESTING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 117. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY ANTIBIOTIC RESISTANCE TESTING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 118. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY ANTIBIOTIC RESISTANCE TESTING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 119. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY PATHOGEN DETECTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 120. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY PATHOGEN DETECTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 121. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY PATHOGEN DETECTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 122. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 123. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY ONCOLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 124. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY ONCOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 125. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 126. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY DIAGNOSTICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 127. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY DIAGNOSTICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 128. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY DIAGNOSTICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 129. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY PROGNOSTICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 130. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY PROGNOSTICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 131. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY PROGNOSTICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 132. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY THERANOSTICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 133. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY THERANOSTICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 134. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY THERANOSTICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 135. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 136. AMERICAS TARGETED SEQUENCING MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 137. AMERICAS TARGETED SEQUENCING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 138. AMERICAS TARGETED SEQUENCING MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 139. AMERICAS TARGETED SEQUENCING MARKET SIZE, BY REAGENTS & KITS, 2018-2032 (USD MILLION)
  • TABLE 140. AMERICAS TARGETED SEQUENCING MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2032 (USD MILLION)
  • TABLE 141. AMERICAS TARGETED SEQUENCING MARKET SIZE, BY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 142. AMERICAS TARGETED SEQUENCING MARKET SIZE, BY AMPLICON SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 143. AMERICAS TARGETED SEQUENCING MARKET SIZE, BY HYBRID CAPTURE, 2018-2032 (USD MILLION)
  • TABLE 144. AMERICAS TARGETED SEQUENCING MARKET SIZE, BY MOLECULAR INVERSION PROBES, 2018-2032 (USD MILLION)
  • TABLE 145. AMERICAS TARGETED SEQUENCING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 146. AMERICAS TARGETED SEQUENCING MARKET SIZE, BY HOSPITALS & DIAGNOSTIC CENTERS, 2018-2032 (USD MILLION)
  • TABLE 147. AMERICAS TARGETED SEQUENCING MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, 2018-2032 (USD MILLION)
  • TABLE 148. AMERICAS TARGETED SEQUENCING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 149. AMERICAS TARGETED SEQUENCING MARKET SIZE, BY BIOMARKER DISCOVERY, 2018-2032 (USD MILLION)
  • TABLE 150. AMERICAS TARGETED SEQUENCING MARKET SIZE, BY GENETIC DISEASES, 2018-2032 (USD MILLION)
  • TABLE 151. AMERICAS TARGETED SEQUENCING MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 152. AMERICAS TARGETED SEQUENCING MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 153. NORTH AMERICA TARGETED SEQUENCING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 154. NORTH AMERICA TARGETED SEQUENCING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 155. NORTH AMERICA TARGETED SEQUENCING MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 156. NORTH AMERICA TARGETED SEQUENCING MARKET SIZE, BY REAGENTS & KITS, 2018-2032 (USD MILLION)
  • TABLE 157. NORTH AMERICA TARGETED SEQUENCING MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2032 (USD MILLION)
  • TABLE 158. NORTH AMERICA TARGETED SEQUENCING MARKET SIZE, BY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 159. NORTH AMERICA TARGETED SEQUENCING MARKET SIZE, BY AMPLICON SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 160. NORTH AMERICA TARGETED SEQUENCING MARKET SIZE, BY HYBRID CAPTURE, 2018-2032 (USD MILLION)
  • TABLE 161. NORTH AMERICA TARGETED SEQUENCING MARKET SIZE, BY MOLECULAR INVERSION PROBES, 2018-2032 (USD MILLION)
  • TABLE 162. NORTH AMERICA TARGETED SEQUENCING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 163. NORTH AMERICA TARGETED SEQUENCING MARKET SIZE, BY HOSPITALS & DIAGNOSTIC CENTERS, 2018-2032 (USD MILLION)
  • TABLE 164. NORTH AMERICA TARGETED SEQUENCING MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, 2018-2032 (USD MILLION)
  • TABLE 165. NORTH AMERICA TARGETED SEQUENCING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 166. NORTH AMERICA TARGETED SEQUENCING MARKET SIZE, BY BIOMARKER DISCOVERY, 2018-2032 (USD MILLION)
  • TABLE 167. NORTH AMERICA TARGETED SEQUENCING MARKET SIZE, BY GENETIC DISEASES, 2018-2032 (USD MILLION)
  • TABLE 168. NORTH AMERICA TARGETED SEQUENCING MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 169. NORTH AMERICA TARGETED SEQUENCING MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 170. LATIN AMERICA TARGETED SEQUENCING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 171. LATIN AMERICA TARGETED SEQUENCING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 172. LATIN AMERICA TARGETED SEQUENCING MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 173. LATIN AMERICA TARGETED SEQUENCING MARKET SIZE, BY REAGENTS & KITS, 2018-2032 (USD MILLION)
  • TABLE 174. LATIN AMERICA TARGETED SEQUENCING MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2032 (USD MILLION)
  • TABLE 175. LATIN AMERICA TARGETED SEQUENCING MARKET SIZE, BY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 176. LATIN AMERICA TARGETED SEQUENCING MARKET SIZE, BY AMPLICON SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 177. LATIN AMERICA TARGETED SEQUENCING MARKET SIZE, BY HYBRID CAPTURE, 2018-2032 (USD MILLION)
  • TABLE 178. LATIN AMERICA TARGETED SEQUENCING MARKET SIZE, BY MOLECULAR INVERSION PROBES, 2018-2032 (USD MILLION)
  • TABLE 179. LATIN AMERICA TARGETED SEQUENCING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 180. LATIN AMERICA TARGETED SEQUENCING MARKET SIZE, BY HOSPITALS & DIAGNOSTIC CENTERS, 2018-2032 (USD MILLION)
  • TABLE 181. LATIN AMERICA TARGETED SEQUENCING MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, 2018-2032 (USD MILLION)
  • TABLE 182. LATIN AMERICA TARGETED SEQUENCING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 183. LATIN AMERICA TARGETED SEQUENCING MARKET SIZE, BY BIOMARKER DISCOVERY, 2018-2032 (USD MILLION)
  • TABLE 184. LATIN AMERICA TARGETED SEQUENCING MARKET SIZE, BY GENETIC DISEASES, 2018-2032 (USD MILLION)
  • TABLE 185. LATIN AMERICA TARGETED SEQUENCING MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 186. LATIN AMERICA TARGETED SEQUENCING MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 187. EUROPE, MIDDLE EAST & AFRICA TARGETED SEQUENCING MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 188. EUROPE, MIDDLE EAST & AFRICA TARGETED SEQUENCING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 189. EUROPE, MIDDLE EAST & AFRICA TARGETED SEQUENCING MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 190. EUROPE, MIDDLE EAST & AFRICA TARGETED SEQUENCING MARKET SIZE, BY REAGENTS & KITS, 2018-2032 (USD MILLION)
  • TABLE 191. EUROPE, MIDDLE EAST & AFRICA TARGETED SEQUENCING MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2032 (USD MILLION)
  • TABLE 192. EUROPE, MIDDLE EAST & AFRICA TARGETED SEQUENCING MARKET SIZE, BY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 193. EUROPE, MIDDLE EAST & AFRICA TARGETED SEQUENCING MARKET SIZE, BY AMPLICON SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 194. EUROPE, MIDDLE EAST & AFRICA TARGETED SEQUENCING MARKET SIZE, BY HYBRID CAPTURE, 2018-2032 (USD MILLION)
  • TABLE 195. EUROPE, MIDDLE EAST & AFRICA TARGETED SEQUENCING MARKET SIZE, BY MOLECULAR INVERSION PROBES, 2018-2032 (USD MILLION)
  • TABLE 196. EUROPE, MIDDLE EAST & AFRICA TARGETED SEQUENCING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 197. EUROPE, MIDDLE EAST & AFRICA TARGETED SEQUENCING MARKET SIZE, BY HOSPITALS & DIAGNOSTIC CENTERS, 2018-2032 (USD MILLION)
  • TABLE 198. EUROPE, MIDDLE EAST & AFRICA TARGETED SEQUENCING MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, 2018-2032 (USD MILLION)
  • TABLE 199. EUROPE, MIDDLE EAST & AFRICA TARGETED SEQUENCING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 200. EUROPE, MIDDLE EAST & AFRICA TARGETED SEQUENCING MARKET SIZE, BY BIOMARKER DISCOVERY, 2018-2032 (USD MILLION)
  • TABLE 201. EUROPE, MIDDLE EAST & AFRICA TARGETED SEQUENCING MARKET SIZE, BY GENETIC DISEASES, 2018-2032 (USD MILLION)
  • TABLE 202. EUROPE, MIDDLE EAST & AFRICA TARGETED SEQUENCING MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 203. EUROPE, MIDDLE EAST & AFRICA TARGETED SEQUENCING MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 204. EUROPE TARGETED SEQUENCING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 205. EUROPE TARGETED SEQUENCING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 206. EUROPE TARGETED SEQUENCING MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 207. EUROPE TARGETED SEQUENCING MARKET SIZE, BY REAGENTS & KITS, 2018-2032 (USD MILLION)
  • TABLE 208. EUROPE TARGETED SEQUENCING MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2032 (USD MILLION)
  • TABLE 209. EUROPE TARGETED SEQUENCING MARKET SIZE, BY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 210. EUROPE TARGETED SEQUENCING MARKET SIZE, BY AMPLICON SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 211. EUROPE TARGETED SEQUENCING MARKET SIZE, BY HYBRID CAPTURE, 2018-2032 (USD MILLION)
  • TABLE 212. EUROPE TARGETED SEQUENCING MARKET SIZE, BY MOLECULAR INVERSION PROBES, 2018-2032 (USD MILLION)
  • TABLE 213. EUROPE TARGETED SEQUENCING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 214. EUROPE TARGETED SEQUENCING MARKET SIZE, BY HOSPITALS & DIAGNOSTIC CENTERS, 2018-2032 (USD MILLION)
  • TABLE 215. EUROPE TARGETED SEQUENCING MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, 2018-2032 (USD MILLION)
  • TABLE 216. EUROPE TARGETED SEQUENCING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 217. EUROPE TARGETED SEQUENCING MARKET SIZE, BY BIOMARKER DISCOVERY, 2018-2032 (USD MILLION)
  • TABLE 218. EUROPE TARGETED SEQUENCING MARKET SIZE, BY GENETIC DISEASES, 2018-2032 (USD MILLION)
  • TABLE 219. EUROPE TARGETED SEQUENCING MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 220. EUROPE TARGETED SEQUENCING MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 221. MIDDLE EAST TARGETED SEQUENCING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 222. MIDDLE EAST TARGETED SEQUENCING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 223. MIDDLE EAST TARGETED SEQUENCING MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 224. MIDDLE EAST TARGETED SEQUENCING MARKET SIZE, BY REAGENTS & KITS, 2018-2032 (USD MILLION)
  • TABLE 225. MIDDLE EAST TARGETED SEQUENCING MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2032 (USD MILLION)
  • TABLE 226. MIDDLE EAST TARGETED SEQUENCING MARKET SIZE, BY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 227. MIDDLE EAST TARGETED SEQUENCING MARKET SIZE, BY AMPLICON SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 228. MIDDLE EAST TARGETED SEQUENCING MARKET SIZE, BY HYBRID CAPTURE, 2018-2032 (USD MILLION)
  • TABLE 229. MIDDLE EAST TARGETED SEQUENCING MARKET SIZE, BY MOLECULAR INVERSION PROBES, 2018-2032 (USD MILLION)
  • TABLE 230. MIDDLE EAST TARGETED SEQUENCING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 231. MIDDLE EAST TARGETED SEQUENCING MARKET SIZE, BY HOSPITALS & DIAGNOSTIC CENTERS, 2018-2032 (USD MILLION)
  • TABLE 232. MIDDLE EAST TARGETED SEQUENCING MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, 2018-2032 (USD MILLION)
  • TABLE 233. MIDDLE EAST TARGETED SEQUENCING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 234. MIDDLE EAST TARGETED SEQUENCING MARKET SIZE, BY BIOMARKER DISCOVERY, 2018-2032 (USD MILLION)
  • TABLE 235. MIDDLE EAST TARGETED SEQUENCING MARKET SIZE, BY GENETIC DISEASES, 2018-2032 (USD MILLION)
  • TABLE 236. MIDDLE EAST TARGETED SEQUENCING MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 237. MIDDLE EAST TARGETED SEQUENCING MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 238. AFRICA TARGETED SEQUENCING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 239. AFRICA TARGETED SEQUENCING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 240. AFRICA TARGETED SEQUENCING MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 241. AFRICA TARGETED SEQUENCING MARKET SIZE, BY REAGENTS & KITS, 2018-2032 (USD MILLION)
  • TABLE 242. AFRICA TARGETED SEQUENCING MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2032 (USD MILLION)
  • TABLE 243. AFRICA TARGETED SEQUENCING MARKET SIZE, BY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 244. AFRICA TARGETED SEQUENCING MARKET SIZE, BY AMPLICON SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 245. AFRICA TARGETED SEQUENCING MARKET SIZE, BY HYBRID CAPTURE, 2018-2032 (USD MILLION)
  • TABLE 246. AFRICA TARGETED SEQUENCING MARKET SIZE, BY MOLECULAR INVERSION PROBES, 2018-2032 (USD MILLION)
  • TABLE 247. AFRICA TARGETED SEQUENCING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 248. AFRICA TARGETED SEQUENCING MARKET SIZE, BY HOSPITALS & DIAGNOSTIC CENTERS, 2018-2032 (USD MILLION)
  • TABLE 249. AFRICA TARGETED SEQUENCING MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, 2018-2032 (USD MILLION)
  • TABLE 250. AFRICA TARGETED SEQUENCING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 251. AFRICA TARGETED SEQUENCING MARKET SIZE, BY BIOMARKER DISCOVERY, 2018-2032 (USD MILLION)
  • TABLE 252. AFRICA TARGETED SEQUENCING MARKET SIZE, BY GENETIC DISEASES, 2018-2032 (USD MILLION)
  • TABLE 253. AFRICA TARGETED SEQUENCING MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 254. AFRICA TARGETED SEQUENCING MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 255. ASIA-PACIFIC TARGETED SEQUENCING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 256. ASIA-PACIFIC TARGETED SEQUENCING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 257. ASIA-PACIFIC TARGETED SEQUENCING MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 258. ASIA-PACIFIC TARGETED SEQUENCING MARKET SIZE, BY REAGENTS & KITS, 2018-2032 (USD MILLION)
  • TABLE 259. ASIA-PACIFIC TARGETED SEQUENCING MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2032 (USD MILLION)
  • TABLE 260. ASIA-PACIFIC TARGETED SEQUENCING MARKET SIZE, BY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 261. ASIA-PACIFIC TARGETED SEQUENCING MARKET SIZE, BY AMPLICON SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 262. ASIA-PACIFIC TARGETED SEQUENCING MARKET SIZE, BY HYBRID CAPTURE, 2018-2032 (USD MILLION)
  • TABLE 263. ASIA-PACIFIC TARGETED SEQUENCING MARKET SIZE, BY MOLECULAR INVERSION PROBES, 2018-2032 (USD MILLION)
  • TABLE 264. ASIA-PACIFIC TARGETED SEQUENCING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 265. ASIA-PACIFIC TARGETED SEQUENCING MARKET SIZE, BY HOSPITALS & DIAGNOSTIC CENTERS, 2018-2032 (USD MILLION)
  • TABLE 266. ASIA-PACIFIC TARGETED SEQUENCING MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, 2018-2032 (USD MILLION)
  • TABLE 267. ASIA-PACIFIC TARGETED SEQUENCING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 268. ASIA-PACIFIC TARGETED SEQUENCING MARKET SIZE, BY BIOMARKER DISCOVERY, 2018-2032 (USD MILLION)
  • TABLE 269. ASIA-PACIFIC TARGETED SEQUENCING MARKET SIZE, BY GENETIC DISEASES, 2018-2032 (USD MILLION)
  • TABLE 270. ASIA-PACIFIC TARGETED SEQUENCING MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 271. ASIA-PACIFIC TARGETED SEQUENCING MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 272. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 273. ASEAN TARGETED SEQUENCING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 274. ASEAN TARGETED SEQUENCING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 275. ASEAN TARGETED SEQUENCING MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 276. ASEAN TARGETED SEQUENCING MARKET SIZE, BY REAGENTS & KITS, 2018-2032 (USD MILLION)
  • TABLE 277. ASEAN TARGETED SEQUENCING MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2032 (USD MILLION)
  • TABLE 278. ASEAN TARGETED SEQUENCING MARKET SIZE, BY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 279. ASEAN TARGETED SEQUENCING MARKET SIZE, BY AMPLICON SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 280. ASEAN TARGETED SEQUENCING MARKET SIZE, BY HYBRID CAPTURE, 2018-2032 (USD MILLION)
  • TABLE 281. ASEAN TARGETED SEQUENCING MARKET SIZE, BY MOLECULAR INVERSION PROBES, 2018-2032 (USD MILLION)
  • TABLE 282. ASEAN TARGETED SEQUENCING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 283. ASEAN TARGETED SEQUENCING MARKET SIZE, BY HOSPITALS & DIAGNOSTIC CENTERS, 2018-2032 (USD MILLION)
  • TABLE 284. ASEAN TARGETED SEQUENCING MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, 2018-2032 (USD MILLION)
  • TABLE 285. ASEAN TARGETED SEQUENCING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 286. ASEAN TARGETED SEQUENCING MARKET SIZE, BY BIOMARKER DISCOVERY, 2018-2032 (USD MILLION)
  • TABLE 287. ASEAN TARGETED SEQUENCING MARKET SIZE, BY GENETIC DISEASES, 2018-2032 (USD MILLION)
  • TABLE 288. ASEAN TARGETED SEQUENCING MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 289. ASEAN TARGETED SEQUENCING MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 290. GCC TARGETED SEQUENCING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 291. GCC TARGETED SEQUENCING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 292. GCC TARGETED SEQUENCING MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 293. GCC TARGETED SEQUENCING MARKET SIZE, BY REAGENTS & KITS, 2018-2032 (USD MILLION)
  • TABLE 294. GCC TARGETED SEQUENCING MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2032 (USD MILLION)
  • TABLE 295. GCC TARGETED SEQUENCING MARKET SIZE, BY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 296. GCC TARGETED SEQUENCING MARKET SIZE, BY AMPLICON SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 297. GCC TARGETED SEQUENCING MARKET SIZE, BY HYBRID CAPTURE, 2018-2032 (USD MILLION)
  • TABLE 298. GCC TARGETED SEQUENCING MARKET SIZE, BY MOLECULAR INVERSION PROBES, 2018-2032 (USD MILLION)
  • TABLE 299. GCC TARGETED SEQUENCING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 300. GCC TARGETED SEQUENCING MARKET SIZE, BY HOSPITALS & DIAGNOSTIC CENTERS, 2018-2032 (USD MILLION)
  • TABLE 301. GCC TARGETED SEQUENCING MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, 2018-2032 (USD MILLION)
  • TABLE 302. GCC TARGETED SEQUENCING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 303. GCC TARGETED SEQUENCING MARKET SIZE, BY BIOMARKER DISCOVERY, 2018-2032 (USD MILLION)
  • TABLE 304. GCC TARGETED SEQUENCING MARKET SIZE, BY GENETIC DISEASES, 2018-2032 (USD MILLION)
  • TABLE 305. GCC TARGETED SEQUENCING MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 306. GCC TARGETED SEQUENCING MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 307. EUROPEAN UNION TARGETED SEQUENCING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 308. EUROPEAN UNION TARGETED SEQUENCING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 309. EUROPEAN UNION TARGETED SEQUENCING MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 310. EUROPEAN UNION TARGETED SEQUENCING MARKET SIZE, BY REAGENTS & KITS, 2018-2032 (USD MILLION)
  • TABLE 311. EUROPEAN UNION TARGETED SEQUENCING MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2032 (USD MILLION)
  • TABLE 312. EUROPEAN UNION TARGETED SEQUENCING MARKET SIZE, BY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 313. EUROPEAN UNION TARGETED SEQUENCING MARKET SIZE, BY AMPLICON SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 314. EUROPEAN UNION TARGETED SEQUENCING MARKET SIZE, BY HYBRID CAPTURE, 2018-2032 (USD MILLION)
  • TABLE 315. EURO